Inventor
DEPLA ERIK
BE47 patents
⚠️ This page may combine multiple inventors who share the name “DEPLA ERIK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABLYNX NV
14 patentsUS9803001B2Oct 31, 2017
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
ABLYNX NV4 citations84
US10550174B2Feb 4, 2020
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ABLYNX NV6 citations82
US9834595B2Dec 5, 2017
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ABLYNX NV6 citations82
US11384151B2Jul 12, 2022
CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
ABLYNX NV2 citations72
US11007146B2May 18, 2021
Methods and compositions for the preparation of aerosols
ABLYNX NV1 citations71
US9725522B2Aug 8, 2017
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
ABLYNX NV2 citations71
US9320792B2Apr 26, 2016
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
ABLYNX NV4 citations71
US11028151B2Jun 8, 2021
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
ABLYNX NV0 citations62
US12221487B2Feb 11, 2025
Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
ABLYNX NV0 citations61
US11518799B2Dec 6, 2022
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ABLYNX NV0 citations61
US12083219B2Sep 10, 2024
Methods and compositions for the preparation of aerosols
ABLYNX NV0 citations60
US11149086B2Oct 19, 2021
KV1.3 binding immunoglobulins
ABLYNX NV0 citations42
US10561805B2Feb 18, 2020
Methods of treating RSV infections
ABLYNX NV0 citations42
US10512739B2Dec 24, 2019
Inhalation device for use in aerosol therapy of respiratory diseases
ABLYNX NV0 citations34
INNOGENETICS NV
11 patentsUS7101561B2Sep 5, 2006
Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
INNOGENETICS NV21 citations92
US6635257B1Oct 21, 2003
Particles of HCV envelope proteins: use for vaccination
INNOGENETICS NV28 citations90
US7238356B2Jul 3, 2007
Core-glycosylated HCV envelope proteins
INNOGENETICS NV24 citations88
US7048930B2May 23, 2006
Expression of core-glycosylated HCV envelope proteins in yeast
INNOGENETICS NV18 citations88
US6521403B1Feb 18, 2003
Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
INNOGENETICS NV7 citations74
US7314925B2Jan 1, 2008
Constructs and methods for expression of recombinant HCV envelope proteins
INNOGENETICS NV8 citations71
US7413741B2Aug 19, 2008
HCV E1 comprising specific disulfide bridges
INNOGENETICS NV8 citations66
US6855318B1Feb 15, 2005
Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
INNOGENETICS NV3 citations63
US6670114B1Dec 30, 2003
Host derived proteins binding HCV: medical, diagnostic and purification use
INNOGENETICS NV4 citations63
US7108855B2Sep 19, 2006
Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
INNOGENETICS NV0 citations52
US6841353B2Jan 11, 2005
Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
INNOGENETICS NV1 citations52
ORIONIS BIOSCIENCES INC
10 patentsUS11440943B2Sep 13, 2022
Therapeutic interferon alpha 1 proteins
ORIONIS BIOSCIENCES INC2 citations72
US12583898B2Mar 24, 2026
Therapeutic interferon alpha 1 proteins
ORIONIS BIOSCIENCES INC0 citations62
US12448447B2Oct 21, 2025
CD8 binding agents
ORIONIS BIOSCIENCES INC0 citations62
US12410225B2Sep 9, 2025
Modulation of dendritic cell lineages
ORIONIS BIOSCIENCES INC0 citations62
US12351633B2Jul 8, 2025
PD-1 and PD-L1 binding agents
ORIONIS BIOSCIENCES INC0 citations62
US12351614B2Jul 8, 2025
CLEC9A-based chimeric protein complexes
ORIONIS BIOSCIENCES INC0 citations62
US12091463B2Sep 17, 2024
Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
ORIONIS BIOSCIENCES INC1 citations62
US11566072B2Jan 31, 2023
CD8 binding agents
ORIONIS BIOSCIENCES INC1 citations62
US11498966B2Nov 15, 2022
PD-1 and PD-L1 binding agents
ORIONIS BIOSCIENCES INC1 citations62
US12583941B2Mar 24, 2026
Fibroblast activation protein binding agents and use thereof
ORIONIS BIOSCIENCES INC0 citations51
BOEHRINGER INGELHEIM INT
5 patentsUS10385134B2Aug 20, 2019
CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
BOEHRINGER INGELHEIM INT3 citations72
US9783612B2Oct 10, 2017
CX3CR1-binding polypeptides
BOEHRINGER INGELHEIM INT2 citations72
US11161916B2Nov 2, 2021
Bispecific binding molecules binding to VEGF and Ang2
BOEHRINGER INGELHEIM INT4 citations70
US10414828B2Sep 17, 2019
Bispecific binding molecules binding to VEGF and Ang2
BOEHRINGER INGELHEIM INT4 citations70
US9458235B2Oct 4, 2016
Method for treating a CX3CR1-associated disease with CX3CR1-binding polypeptides
BOEHRINGER INGELHEIM INT2 citations61
DEPLA ERIK
3 patentsUS8945567B2Feb 3, 2015
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
DEPLA ERIK8 citations82
US9644022B2May 9, 2017
Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
DEPLA ERIK4 citations71
US9713589B2Jul 25, 2017
Methods and compositions for the preparation of aerosols
DEPLA ERIK4 citations70